A complete application in a minute
Tailored resume and cover letter, ready to send.
NIBRT invites applications for a Postdoctoral Researcher in Formulation Science focused on enhancing stability and deployability of a Lassa fever vaccine. The role engages with EU-funded consortia and cross-disciplinary partners to develop thermostable vaccine formulations and evaluate them through preclinical stages.
You will design and execute experiments, maintain rigorous data integrity, mentor junior researchers, and prepare reports for stakeholders.
Organisation/Company NIBRT Research Field Other Researcher Profile Recognised Researcher (R2) Positions Postdoc Positions Application Deadline 30 Nov 2026 - 17:00 (Europe/Dublin) Country Ireland Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework Programme? Other EU programme Is the Job related to staff position within a Research Infrastructure? No
Project Title: Formulation Innovation to Enhance Thermal Stability and Deployability of a Lassa Fever Vaccine
Vaccine deployment is severely constrained by the need for logistics including cold chain distribution. Infectious diseases remain a major threat to health and health security in the EU and globally and thus a proactive approach to the development of vaccines in preparedness for future infectious disease outbreaks is needed. One such threat is Lassa mammarenavirus, which remains a major epidemic threat in West Africa and a priority pathogen for global health security. Our partners have successfully developed a live recombinant virus vector Lassa vaccine to clinical testing. However, this vaccine currently requires ultra-cold chain storage with limited refrigerator stability. This creates challenges for broad deployment and storage, particularly for rapid use in an outbreak response and for routine preventive use in endemic settings in resource-limited regions.
In this Horizon-EU funded project, the consortium will advance this Lassa vaccine candidate toward a next-generation formulation optimized for epidemic deployment. Specifically, the partners will develop and eval-uate a thermostable formulation manufactured using scalable, production technologies and advance it through required preclinical testing and first in human clinical evaluation. Scientists in the Vaccine Immun-isation Technology and Access (VITAL) group in NIBRT will collaborate with the vaccine manufacturing part-ner to identify, develop and verify thermostabilising formulations and processes for this live virus vector vac-cine. We will focus on developing a liquid and a lyophilised vaccine form.
The key responsibilities of the job include:
Research Field Other Education Level PhD or equivalent
Skills/Qualifications